Healthcare Utilization and PROMs do not vary by BMI class in medial UKA

Shujaa T Khan¹, Nickelas Huffman, Benjamin Edward Jevnikar, Ignacio Pasqualini, Chao Zhang, Lakshmi Spandana Gudapati, Matthew Edward Deren¹, Trevor G Murray, Nicolas Santiago Piuzzi ¹Cleveland Clinic

INTRODUCTION:

Obesity has long been considered a relative contraindication to medial unicompartmental knee arthroplasty (mUKA). However, with improved implants and techniques, this criteria for UKAs have been challenged. This study aimed to assess the association of BMI with (i) healthcare utilization and (ii) patient reported outcome measures (PROMs) in patients undergoing mUKA.

METHODS:

We prospectively enrolled 886 patients who underwent mUKA from 2016 to 2022 at a tertiary academic center in the USA. Patients were assigned into five groups based on their BMI before surgery: normal (18.5-24.9kg/m²), overweight (25-29.9), obese I (30-34.9), obese II (35-39.9), and obese III group (\geq 40). Outcomes included length of stay (LOS), discharge disposition (DD), 90-day readmission, 90-day ED visits, 1-year and 2-year reoperation, and 1-year PROMs: Knee disability and Osteoarthritis Outcome Score for Pain (KOOS Pain), Physical function Shortform (KOOS PS), and Joint Replacement (KOOS JR). Achievement of the Minimal Clinically Important Difference (MCID) and Patient Acceptable Symptom State (PASS) threshold were assessed for each PROMs subscales. Multivariable regression models were used to compare outcomes. For LOS, DD, readmission, 1-year reoperation, 2-year reoperation, and mortality, no modeling was done due to the small event sizes and will be summarized by BMI below/above 35. All tests were two sided, assuming a significant level of 0.05. Cohort characteristics can be found in **Table 1**. RESULTS:

There were no significant differences in LOS (p=0.627), DD (p=1.0), and 90-day readmissions after mUKA (p=0.783) between patients with BMI below and above 35 (**Table 2**). Similarly, there were no significant differences in 2-year reoperation rates between BMI <35 (4.2%) and BMI \ge 35 (3.8%). 1-year mortality in this entire cohort was 0% (**Table 2**). A large majority of patients in each BMI group achieved MCID and PASS thresholds (**Table 3**). After adjusting for possible confounders, BMI was not associated with failing to achieve MCID in any of the KOOS subscales (**Table 3**). Similarly, BMI was not associated with PASS threshold failure in any of the KOOS domains (**Table 5**). Satisfaction at 1-year postoperatively was not significantly associated with BMI (p=0.6) (**Table 5**).

DISCUSSION AND CONCLUSION:

BMI does not significantly impact healthcare utilization, reoperation rates, or clinically significant improvements in knee pain and function following mUKA. Obese and morbidly obese patients reported similar levels of improvement as those with normal BMI. Therefore, using BMI as a relative contraindication for mUKA may be unwarranted based on these outcomes. Future research should focus on long-term implant survivorship and identifying risk factors for revisions in this patient population.

| | Table 2 - Healthcare Utilization and Mortality | Table 3 - Summary statistics of achievement of MCID and PAXS Thresholds by RMI | Table 4 – Multi-variable logrids regression model, using failure to reach MCID improvements in KOOS Pain, 75, and JR is outcomes. | Table 5 - Multivasiable logistic supression model results, using failures to reach attalament of PS65 throubable in XXXVIII Para PS. 20 and Satisfarian an optimum. |
|--|--|---|---|--|
| Variable Level All (u=886) Normal IX.5 Overweight 35:29:3 Obsect 13.6 | Variable Level All (a=886) Relev.25 35 and Above p-value (a=755) (a=131) P-value | Narnal Ownersight Obses I Obses III Variable Level All (n=86) 18.5 24.9 25.25.5 56.34.5 35.39.9 >=6 P-value (n=14) (n=46) (n=350) (n=250) (n=26) (n=26) | Pela MCB (Fellers) P5 MCB (Fellers) IR MCB (Fellers) Produces 08 (2010) P-value Queuel (08 (2010) P-value Queuel (08 (2010) P-value Queuel | Prin PANS (Enlanc) PS-PASS-(Enlanc) AR PANS (Enlanc) Solidarios (Enlanc) |
| Age (7.0 65.0 66.0 60.0 60.0 60.0 60.0 60.0 60 | LOS >= 3 9 (1.02%) 7 (0.93%) 2 (1.53%) 0.627 | Pair MCID Imported 411 (02.2%) 128 (01.0%) 236 (03.2%) 231 47 (03.1%) 28 (110%) 0129 | | Polician 08, Folia 9 09, Folia |
| 5xx F 634 (51.2%) 54 (61.8%) 546 (61.2%) 128 (69.8%) 56 (60.2%) 1788 (76.9%) M 432 (65.8%) 52 (56.8%) 204 (55.3%) 138 (55.2%) 34 (53.6%) 11 (55.3%) | Discharge Non-home 5 (0.58%) 4 (0.53%) 1 (0.78%) 1.000 | 7.39 (90.0%) Failure 66.07.57% 12.05.57% 22.05.52% 24.05.45%7.05.0%% 9.05.00% | BDat 0.42 0.279 0.179 1.67 0.839 0.124 0.12 0.421 0.4 | IM 1.0 070 0204 1.0 0.94 0.016 1.0 0.05 0.259 0.0 0.75 0.005 Overwardt 0.54- 0.54- 0.78- 0.79- |
| IDMI 29.1 21.3 27.4 12.3 37.1 65.9 66.064 [15:592.29] [22:12.34.1] [16:23.51] [11:23.54] [16:03.51] 60.064 Edecation 16.6 15.8 15.9 15.8 16.0 16.0 60.064 | Home/ home health care 881 (99.4%) 751 (99.5%) 130 (99.2%) | PS MCDD Improved 696 (01.7%) 114 (01.4%) 211 (03.6%) 196 83 (03.0%) 22 (70.6%) 0.684 8.04 (79.0%) | BMI (Obere 1.52 0.319 1.54 0.043 2.12 0.039 Ev Namaab (0.67-3.47) (1.82-3.67) (0.97-4.61) (0.97-4.61) | vNema[189 170 209 142 |
| AIN (12/03/0) [12/03/0] [12/03/0] [12/03/0] [12/03/0] 45.0 (99.0 (0.0 50.0 50.0 50.0 50.0 50.0 50.0 50 | 90-day 27 (3.09%) 24 (3.19%) 3 (2.29%) 0.783 | Talum 156(18.7%) 25(18.6%) 55(18.6%) 52(21.0%)66(18.2%) 6(21.6%) JR MCBD Improved 677(08.7%) 187(08.2%)275(03.6%) 187 54(09.3%) 20(08.9%)0600 | IDHI (Obese 0.54 0.506 1.40 0.406 1.18 0.750 IF v (0.51 = 2.82) (0.40 = 3.13) (0.40 = 3.21) | Bid(Obse) 1.56 0.278 1.27 0.301 1.49 0.158 1.16 0.639 1 v Sumult) 0.78 - 0.084 - 0.064 - 0.044 - 1.00 2.00 2.401 2.00 - 0.044 - |
| Rear Wein 972(41:39) 10 (0139) 127(4139) 227(0139) 121 (0121) Newhile 74(05596) 9(8479) 157(5220) 27(0279) 11(17709) 10(199) Smoking News 122(2139) 26(539) 26(539) 26(529) 137(1874) 53(5474) 13(1049) 10(1049) 1000 | 2-year Respectation 37 (4.18%) 32 (4.24%) 5 (3.82%) 1.000 | 6.74 04.076 13(10.776 13(10.276) 14(15.076) | Normal) BOR (Obese 0.00 0.33) 1.62 0.460 1.38 0.856 HT v (200000.000 0.33) 0.642-0.870 0.252-0.590 | INCODese 140 0277 1.06 8.00 1.16 6.04 1.16 0.009 ITYNemi0 0.77- 0.57- 0.78- 0.57- |
| Quit 331.07.4% 59.041.2% 126.06.0% 97.06.7% 29.07.5% 11.08.5% Current 49.04.8% 4.0.5% 18.0.1% 19.0.02% 4.01.8% 27.04% | 1-year Martality No 886 (100%) 755 (100%) 131 (100%) . | PASS Pain Improved 600.088.5%0 105.075.076.247.071.0%0 167 60.058.8%0 20.071.4%00.053 | Normal) | 230 240 240 230 |
| Inversion Other 337(45.1%) 12(41.8%) 134(37.8%) 396(46.1%) 49(33.5%) 44(55.9%) 0.057 Moldoni/Me 444(55.9%) 12(51.8%) 139(62.4%) 124(51.9%) 48(48.5%) 9(38.1%) district district | Continuous variables presented as Median (2003, Compariad variables presented as N isolana Ni. | 77,7 (05.3%) Follow 274/01.3% 35/25.0% 181(29:0%) 88/04.3%042(41.2%) 8/28.0%0 | This model was separated for Apr. Son, Bann, Education, Studiang, ABI, OCL, Instrumen, Diagnosis, Asserbasis, OCL and PRION Planotype. | 200,006ee 647 039 0.01 8240 042 0.07 9.46 9.20 Er 0.05- 0.05- 0.21- 0.02- Nom0 149 150 150 |
| Presetype PARANCE - 1912(23:94) 22(23:96) 41 (23:29) 45 (23:39) 44 (33:09) 44 (34:09) 46005 PARMACE - 224(23:29) 50 (23:09) 131 (21:29) 57 (22:29) 15 (14:09) 4 (14:39) PARMACE - 51 (23:09) 7 (14:09) 23 (3:39) 13 (3:09) 51 (23:09) 51 (23:09) | | PASS PS kappoond 568 (66.5%) 98 (10.0%) 230 (88.5%) 159 61 (01.0%) 18 (64.1%) 0.08 (94.1%) 30.3 (64.1%) | | This and it we apart the type, Son, Stars Education, Starling, ASE, OT, Sourcess, Disposes, Howdress, OT, and PDD (Princips, |
| P-95-3628 43 (4.04%) 5 (3.39%) 14 (4.02%) 15 (3.79%) 7 (6.05%) 2 (7.34%) P-95-362% 14 (4.03%) 27 (3.8%) 15 (3.3%) 42 (6.2%) 14 (3.3%) 4 (4.13%) P-95-362% 44 (6.23%) 6 (4.23%) 15 (3.38%) 15 (6.13%) 4 (4.13%) P-95-362% 44 (6.23%) 6 (4.23%) 15 (3.13%) 15 (6.13%) 4 (6.13%) | | Fadure 286 (33.5%) 42 (30.0%) 186 (31.5%) 89 (35.9%)08 (34.4%) 10 (35.7%) PANNAR Improved 407 (05.5%) 38 (33.3%) 207 (09.7%) 133 54 (34.1%) 15 (98.2%)04.083 | | |
| PARAMER 111(23%) 16(127%) 46(132%) 33(22%) 12(11%) 27(13%) PARAMES 51(23%) 16(59%) 12(52%) 12(52%) 12(52%) 12(13%) Anothesis Gravel 31(437%) 42(43%) 12(43%) 12(13%) 12(13%) 12(13%) 51(437%) 12(13 | | 70.3 (00.2%) Fadam 258 (34.2%) 32 (35.7%) 90 (31.3%) 88 (38.8%)90 (31.9%) 7 (31.8%) | | |
| Spinal 457 (21,04) 78 (54,79) 771 (48,99) 153 (22,70) 96 (28,316) 44 (51,04) Other 42 (47,94) 32 (21,96) 35 (21,96) 35 (21,96) 42 (31,94) Diagnesis Nucl.A. 51 (57,76) 15 (52,96) 15 (20,96) 6 (21,96) 12 (21,96) | | PANS 701 00.0%0 113 00.0%0 283 00.0%0 282 (72.0%0 22 (78.0%0.300 (79.0%0) | | |
| CA. 876-09.490 137-09.390 344-09.490 257-09.490 301-00090-26-04.390 | | | | |